Every Form 4 that CeriBell, Inc. (CBLL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CBLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBLL filings page.
Ceribell, Inc. Chief Revenue Officer Joseph S. Manni reported an open-market sale of 768 shares of common stock on February 23, 2026 at $19.79 per share. According to the notes, these shares were sold to cover tax withholding obligations from vesting restricted stock units. After this transaction, he directly owned 26,933 shares, which includes 300 shares acquired under the company’s Employee Stock Purchase Plan on January 30, 2026.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported an open-market sale of 705 shares of common stock at $19.79 per share. According to the disclosure, the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units. After this transaction, Woo directly holds 166,912 shares of Ceribell common stock.
Ceribell, Inc. Chief Financial Officer Scott Blumberg reported an open-market sale of 808 shares of common stock on February 23, 2026 at a price of $19.79 per share. The sale was made to cover tax withholding obligations related to vesting restricted stock units. Following this transaction, he directly holds 118,334 shares, which includes 300 shares acquired under Ceribell's Employee Stock Purchase Plan on January 30, 2026.
Ceribell, Inc. President and CEO Chao Xingjuan reported an open-market sale of 2,084 shares of common stock on February 23, 2026 at $19.79 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.
After this transaction, she directly owned 725,164 common shares. The filing also notes an indirect holding of 369,088 shares through the ACP 2021 Trust, where she is a co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership beyond her pecuniary interest.
Ceribell, Inc. director Josef Parvizi, through the Josef Parvizi Trust, sold 16,714 shares of common stock in open-market transactions on February 19, 2026 under a Rule 10b5-1 trading plan adopted on August 18, 2025.
The weighted average sale price was $20.27 per share, with individual trades between $20.00 and $20.77. Following the sale, the Josef Parvizi Trust held 722,652 shares. Separate Innovation ACP Trust and ACP 2021 Trust holdings were 907,911 and 369,088 shares, respectively, where Parvizi is a co-trustee and may be deemed to share beneficial ownership but disclaims it except to the extent of his pecuniary interest.
Ceribell, Inc. director Josef Parvizi reported automatic sales of common stock through trusts associated with him. A total of 8,286 shares were sold in open-market transactions at a weighted average price of about $20 per share under a Rule 10b5-1 trading plan adopted on August 18, 2025. The Josef Parvizi Trust now holds 739,366 shares indirectly, while the Innovation ACP Trust and ACP 2021 Trust hold 907,911 and 369,088 shares indirectly, respectively.
Ceribell, Inc. President, CEO and director Xingjuan (Jane) Chao reported a series of planned stock transactions on February 4, 2026 under a Rule 10b5-1 trading plan adopted on September 12, 2025. She sold 14,000 shares of common stock at a weighted average price of $20.16, with individual sale prices ranging from $19.87 to $20.61.
On the same date she exercised stock options for 1,446 shares and 23,554 shares at an exercise price of $4.70 per share and sold the same numbers of shares at a weighted average price of $20.16. Following these transactions, she beneficially owned 727,248 shares of Ceribell common stock directly and 369,088 shares indirectly through the ACP 2021 Trust, where she is a co‑trustee and disclaims beneficial ownership except to the extent of her pecuniary interest.
Ceribell, Inc. officer David Foehr reported option exercises and share sales in company stock. On February 3, 2026, he exercised options to buy 3,403 and 2,153 shares at $4.70 per share and then sold the same amounts at $20.00 per share under a prearranged Rule 10b5-1 trading plan.
After these transactions, Foehr directly owned 18,900 shares of Ceribell common stock and held stock options covering 59,598 and 57,445 shares. The option grant vests 25% on May 31, 2023, with the remainder vesting in 36 equal monthly installments.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported planned option exercises and share sales in company stock. On February 2, 2026, he exercised several stock options at prices of $2.24 and $4.70 per share and sold the resulting common shares at weighted average prices around $20.57, all under a pre‑established Rule 10b5‑1 trading plan adopted on May 28, 2025.
Following these transactions, Woo directly beneficially owned 167,617 shares of Ceribell common stock, which includes 300 shares acquired through the company’s employee stock purchase plan on January 30, 2026. He also continues to hold multiple stock options that remain outstanding, some of which are fully vested and currently exercisable and others that continue to vest monthly from April 1, 2023.
Josef Parvizi Trust, an entity associated with Ceribell director Josef Parvizi, sold 25,000 shares of Ceribell common stock on January 15, 2026 at a weighted average price of $22.94 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2025, meaning the trades were pre-arranged rather than discretionary on the trade date. After the sale, the Josef Parvizi Trust held 747,652 shares, while the Innovation ACP Trust held 907,911 shares and the ACP 2021 Trust held 369,088 shares, all reported as indirectly owned, with beneficial ownership disclaimed except to the extent of pecuniary interest.
Ceribell, Inc. insider activity: Chief Revenue Officer Joseph S. Manni reported a disposition of 660 shares of Ceribell common stock on November 20, 2025, at a price of $13.64 per share under transaction code "F." After this transaction, he beneficially owned 27,401 shares of common stock in direct ownership. A footnote explains that this total includes 300 shares previously acquired through the company’s Employee Stock Purchase Plan on July 31, 2025.
Ceribell, Inc. Senior VP, Finance and PAO David Foehr reported multiple equity transactions in company stock. On November 20, 2025, 484 shares of common stock were disposed of at $13.64 per share in a transaction coded "F," typically used for tax withholding. On January 5, 2026, he exercised stock options to acquire 3,403 and 2,153 shares of common stock at an exercise price of $4.7 per share and then sold 3,403 and 2,153 shares at $22.6 per share the same day. These sales were made under a pre-arranged Rule 10b5-1 trading plan. After the reported transactions, he held 18,900 shares of common stock directly.
Ceribell, Inc. President and CEO Xingjuan (Jane) Chao, who is also a director, reported multiple equity transactions in Ceribell common stock and stock options. On 11/20/2025, 2,887 shares of common stock were withheld at $13.64 per share in a transaction coded "F", leaving 795,248 shares held directly. On 01/05/2026, she exercised stock options at an exercise price of $4.70 per share and sold the resulting shares in several transactions pursuant to a Rule 10b5-1 trading plan, including a sale of 54,000 shares at a weighted average price of $21.31. After these trades, she directly owned 741,248 shares of common stock. Separately, an additional 369,088 shares of common stock are reported as indirectly owned through the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership except to the extent of her pecuniary interest. The underlying options reported have expiration dates in 2033 and vest monthly from April 1, 2023.
Ceribell, Inc. filed a Form 4 reporting recent stock transactions by its Chief Technology Officer. On 11/20/2025, 687 shares of common stock were withheld or disposed of at $13.64 in a transaction coded “F,” typically used for tax withholding.
On 01/02/2026, the CTO exercised multiple stock options and immediately sold the resulting shares in pre-planned trades under a Rule 10b5-1 trading plan. Options with exercise prices of $2.24 and $4.70 were exercised in blocks of 1,472, 3,025 and 6,615 shares, followed by sales coded “S” at weighted-average prices of $21.29, $21.18 and $21.16.
After these transactions, the reporting person beneficially owned 167,317 shares of Ceribell common stock, which includes 300 shares acquired through the company’s employee stock purchase plan. The filing also notes outstanding stock options that are vested or continue to vest over time, extending to expiration dates in 2029 and 2033.
Ceribell, Inc. director Rebecca B. Robertson reported an option exercise and share sale. On January 2, 2026, she exercised a stock option for 2,500 shares of common stock at $2.24 per share, then sold 2,500 common shares at $21.89 on the same date. After these transactions, she directly held 19,576 shares of common stock and 7,650 stock options. The filing notes that the transactions were made under a Rule 10b5-1 trading plan that she had previously adopted, and that the stock option is fully vested and currently exercisable.
Ceribell, Inc. director Rebecca B. Robertson reported a sale of common stock and corrected a prior insider filing. On 06/17/2025, she sold 7,445 shares of Ceribell common stock at a weighted average price of $17.63, in transactions executed under a pre-established Rule 10b5-1 trading plan. After this sale, she beneficially owned 21,230 shares of common stock directly. This amended Form 4 removes a previously reported transaction on 06/18/2025 for 11,188 shares that was incorrectly attributed to her, with no other changes made.
Ceribell, Inc. director Josef Parvizi reported an insider stock sale. On 12/15/2025, a trust related to him sold 25,000 shares of Ceribell common stock at a weighted average price of $21.49 per share in transactions executed under a Rule 10b5-1 trading plan. After this sale, he indirectly held 772,652 shares through the Josef Parvizi Trust, 907,911 shares through the Innovation ACP Trust, and 369,088 shares through the ACP 2021 Trust. He serves as trustee or co-trustee of these trusts and may be deemed to have beneficial ownership of the securities, but disclaims beneficial ownership except to the extent of his pecuniary interest.
Ceribell, Inc. (CBLL) President, CEO and Director Xingjuan (Jane) Chao reported option exercises and share sales on 11/21/2025. She exercised stock options to acquire 25,000 shares at $2.24 and 25,000 shares at $3.65, then sold 50,000 common shares at a weighted average price of $15.13, with individual trades between $15 and $15.20. The transactions were effected under a Rule 10b5-1 trading plan. Following these trades, she directly owned 798,135 shares and indirectly held 369,088 shares through the ACP 2021 Trust. Her remaining stock options included 27,551 options at $2.24 expiring on June 10, 2029 and 257,100 options at $3.65 expiring on June 10, 2031. The filing also notes a correction to prior reports that had omitted 25,000 shares from earlier option exercises.
Ceribell (CBLL) reported insider activity by its Chief Technology Officer, Raymond Woo. On 11/11/2025, he exercised options for 1,472 shares at $2.24, and 3,025 and 6,615 shares at $4.70, then sold 11,112 shares under a Rule 10b5-1 trading plan. The sale’s weighted-average price was $12.28, with trades ranging from $12.00 to $12.52. Following these transactions, his directly held common stock was 167,704 shares. Related options remain outstanding with expirations through 2033 as disclosed.